Hyderabad: Hyderabad-based MedleyMed, a subsidiary of Athena Global Technologies, has entered US and other global markets with a suite of digital health solutions for pharmacy businesses and patient care through telemedicine. The company is also expanding its operations in India by 2021-end.
The company’s B2B, B2C solutions and telemedicine platform enables patient care while making it easy for pharmacies to purchase medicines through the epharmacy platform. Its software-as-a-service (SaaS)-based telemedicine platform will also help hospitals.
M Satish, MD, Athena Global Technologies and MedleyMed said, “We had been working on our platforms for epharmacy and telemedicine in the last five years. We found a large gap in the epharmacy space across markets and are coming out with a hyperlocal format. Our 100-member team in Hyderabad had been instrumental in the development of the digital suites. We are keen to more than double our headcount in India and overseas in the next 1-2 years. We will also make inroads into tier-3 and tier-4 locations besides larger cities with our services.”
“Globally, Covid-19 has facilitated and accelerated a massive uptake of digital health solutions and the healthcare providers and consumers continue to view digital solutions as an important modality for their future care needs. With an existing suite of business offerings in B2B and B2C healthcare platforms, we see great potential in the global market and have decided to expand our business operations,” he added.
MedleyMed’s advantages include flexibility in terms of deploying offerings including SaaS, platform-as-a-service, licence or white-label and the ability to achieve customisation to the existing platform to fit the US market and customer needs. The company will create a B2C format for telemedicine soon. “We have got early adopters in the US, which gave us the confidence to foray there. We also evaluated the South Africa market and saw great market potential,” Satish informed.
When asked about setting up global offices, he said, “We will set up a subsidiary in the US to comply with the market regulations. Our expansion will be directly proportionate to the investment we will be making in the next 1-2 years across the markets.”
Source: telanganatoday.com
